Former Bausch + Lomb CEO Saunders to head Forest; Icahn approves
This article was originally published in Scrip
Executive Summary
After Brent Saunders saw Bausch + Lomb through a transformation that made the company attractive to recent acquirer Valeant Pharmaceuticals, industry observers wondered where the Schering-Plough veteran would work his magic next, and now they have their answer: Forest Laboratories.
You may also be interested in...
Activist Investors Seek Action At Allergan, But Are They Aligned?
Investors want to separate the CEO and chairman roles held by Brent Saunders, among other demands, but it's unclear whether new investor Carl Icahn – a prior Saunders supporter – will pursue the same causes.
Italfarmaco To Seek Givinostat Approvals After Phase III Success In DMD
Italfarmaco’s HDAC inhibitor helped ambulatory Duchenne muscular dystrophy patients climb stairs faster than non-treated boys while Capricor’s cell therapy improved upper limb function in non-ambulatory patients.
Finance Watch: Venture Floodgates Open With New Funds, Dozens Of Rounds
Private Company Edition: While the tough state of financing for publicly traded drug developers continues, venture capital firms and private biopharma companies revealed billions of dollars in new VC funds and start-up financings, including $100m-plus mega-rounds for Tessa, Alladapt and ImCheck.